Let's be honest - what are they going to try and argue?
"Our sales went from $0 to some small number, and now are back at Zero. We told the market there were issues getting the product to Australia which dragged on over 12 months and specifically stated this is a Health Canada permit issue and NOT Medcan. Now that we don't have sales Medcan must pay up for millions of lost revenue.."?
CGB shareholders paid for services they didnt receive it seems. That cost CGB shareholders money in lost sales.
Well, no. The whole court action has been brought to light as CGB didn't pay for 12 months at all. Seems to me that Medcan were generous in providing any assistance with imports during the period they were not paid.
Anyone who read the recompliance prospectus in 2019 knew the term of the agreement and would have started a plan B. Why wasn't an internal license application made to the ODC when they took over MCL?
- Forums
- ASX - By Stock
- CGB
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online